Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer

Philip Mack, Angela M. Davies, Primo N Lara, Paul H. Gumerlock, David R Gandara

Research output: Contribution to journalArticle

60 Scopus citations

Abstract

PS-341, a potent and selective proteasome inhibitor, is the prototype for a new class of therapeutics that targets the ubiquitin-proteasome pathway. It is active as a single agent and potentiates chemotherapy and radiation in pre-clinical models. Early phase clinical studies have demonstrated tolerability and activity in multiple myeloma, lymphoma, prostate cancer and lung cancer. By its mechanism of inhibiting protein degradation, PS-341 targets a wide-range of pathways that are relevant to tumor progression and therapy resistance, and can directly modulate expression of cyclins, p27Kip1, p53, NF-κB, Bcl-2 and Bax. PS-341 is currently in phase I/II clinical development in lung cancer. This paper will review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer.

Original languageEnglish (US)
JournalLung Cancer
Volume41
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 1 2003

Keywords

  • Lung cancer
  • Proteasome inhibitor
  • PS-341

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer'. Together they form a unique fingerprint.

  • Cite this